Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Mar 5, 2026

Evaluation of a Reliable Biomarker in a Cecal Ligation and Puncture-Induced Mouse Model of Sepsis
05:28

Evaluation of a Reliable Biomarker in a Cecal Ligation and Puncture-Induced Mouse Model of Sepsis

Published on: December 9, 2022

4.5K

Improved Risk Stratification in Pediatric Septic Shock Using Both Protein and mRNA Biomarkers. PERSEVERE-XP.

Hector R Wong1,2, Natalie Z Cvijanovich3, Nick Anas4

  • 11 Division of Critical Care Medicine, Cincinnati Children's Hospital Medical Center and Cincinnati Children's Research Foundation, Cincinnati, Ohio.

American Journal of Respiratory and Critical Care Medicine
|March 22, 2017
PubMed

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The ARDS, Pneumonia, and Sepsis (APS) Consortium: Rationale, Design, and Feasibility of a National Platform for Phenotyping Critical Illness Syndromes.

Chest·2026
Same author

Metformin on the Presence of COVID-19 Symptoms 6 Months after Infection: The ACTIV-6 Randomized Clinical Trial.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Multisite evaluation of automated electronic case report form data entry from electronic health records.

Journal of biomedical informatics·2026
Same author

External Validation, Molecular Signatures, and Therapeutic Relevance of Pediatric Sepsis-Associated Acute Kidney Injury Subphenotypes.

Critical care medicine·2026
Same author

Characteristics of interventional clinical trials registered in ClinicalTrials.gov, 2018-2023.

Journal of clinical and translational science·2026
Same author

Plasma chondroitin sulfate predicts the effectiveness of fluid resuscitation strategies in patients with sepsis.

The Journal of clinical investigation·2026
Summary

A new model, PERSEVERE-XP, improves pediatric sepsis mortality risk prediction by incorporating additional genes. This enhanced model, linked to TP53, offers better stratification for children with septic shock.

Area of Science:

  • Pediatric critical care medicine
  • Biomarker discovery
  • Genetics and genomics in sepsis

Background:

  • The Pediatric Sepsis Biomarker Risk Model (PERSEVERE) was previously developed to assess mortality risk in pediatric septic shock.
  • PERSEVERE utilized serum proteins linked to 80 mortality risk genes, leaving 68 genes unexamined.
  • Septic shock pathophysiology involves complex genetic and molecular pathways influencing mortality.

Purpose of the Study:

  • To evaluate if incorporating 68 previously unconsidered genes can enhance the predictive performance of the PERSEVERE model.
  • To gain biological insights into the pathophysiology of pediatric septic shock through gene network analysis.
  • To develop an improved risk stratification tool for 28-day mortality in pediatric septic shock.

Main Methods:

Keywords:
biomarkersmortalitysepsisstratification

Related Experiment Videos

Last Updated: Mar 5, 2026

Evaluation of a Reliable Biomarker in a Cecal Ligation and Puncture-Induced Mouse Model of Sepsis
05:28

Evaluation of a Reliable Biomarker in a Cecal Ligation and Puncture-Induced Mouse Model of Sepsis

Published on: December 9, 2022

4.5K
  • Variable reduction identified biologically linked genes from the 68 unconsidered genes, revealing an 18-gene network associated with TP53.
  • A novel risk stratification model, PERSEVERE-XP, was derived using classification and regression tree methodology, combining PERSEVERE probability with new gene data.
  • The PERSEVERE-XP model was validated in independent derivation (n=307) and test (n=77) cohorts.

Main Results:

  • PERSEVERE-XP demonstrated superior performance compared to PERSEVERE in predicting 28-day mortality.
  • In the derivation cohort, PERSEVERE-XP achieved an AUC of 0.90 (95% CI, 0.85-0.95).
  • In the test cohort, PERSEVERE-XP showed an AUC of 0.96 (95% CI, 0.91-1.0), confirming its robust predictive capability.

Conclusions:

  • PERSEVERE-XP integrates protein and mRNA biomarkers for improved mortality risk stratification in pediatric septic shock, suggesting clinical utility.
  • The model's performance enhancement highlights the significant role of TP53-related pathways in cellular division, repair, and metabolism in septic shock.
  • PERSEVERE-XP represents a significant advancement over PERSEVERE, offering a more comprehensive approach to risk assessment in critically ill children.